Skip to content
    Clinical Trials

    Selinexor-lenalidomide maintenance trial halted for futility in myeloma

    Rees et alBritish Journal of Haematology

    Selinexor-lenalidomide maintenance trial halted for futility in myeloma
    The open-label, randomized phase 3 ALLG MM23 (SeaLAND) trial evaluated the efficacy and safety of adding low-dose weekly selinexor (40 mg) to lenalidomide maintenance (selinexor-R) compared to standard lenalidomide maintenance alone (R) following autologous haematopoietic stem cell transplantation (ASCT) in 142 newly diagnosed, transplant-eligible multiple myeloma patients (R = 64; selinexor-R = 78). The trial was halted early due to futility.
    At best response, patients in the selinexor-R arm demonstrated a numerically higher complete response (≥CR) rate compared to the R arm (67% vs. 53%), though this difference did not reach statistical significance (p = 0.09). At a median follow-up of 24 months, progression-free survival (PFS) was comparable between groups, with an estimated hazard ratio of 1.22 (95% CI, 0.62–2.41; p = 0.56). The 24-month PFS rates were 70% (95% CI, 56%–81%) for selinexor-R and 73% (95% CI, 57%–84%) for lenalidomide monotherapy.
    The combination regimen severely affected treatment tolerability and dose delivery. The mean relative dose intensity (RDI) of lenalidomide was significantly reduced in the selinexor-R cohort compared to the R cohort (68% vs. 81%, p = 0.002), while the mean RDI of selinexor reached only 55%. Grade ≥3 adverse events were almost twofold higher with selinexor-R compared to lenalidomide alone (85% vs. 45%, p < 0.001). Specifically, severe non-haematological toxicities were significantly more frequent in the selinexor group, including grade ≥3 infections (19% vs. 6%, p < 0.01) and grade ≥3 gastrointestinal disorders (14% vs. 3%, p < 0.05).
    Given the absence of PFS prolongation, lack of benefit in high-risk subgroups, and substantial increase in severe toxicities that impaired standard lenalidomide dosing, the investigators concluded that selinexor-lenalidomide maintenance cannot be recommended for the general post-transplant multiple myeloma population.

    Key Takeaways

    • In the randomized phase 3 SeaLAND trial, adding weekly selinexor to lenalidomide maintenance did not improve progression-free survival compared with lenalidomide alone (HR = 1.22; 95% CI, 0.62–2.41; p = 0.56; 24-month PFS: 70% vs. 73%), prompting early study termination for futility.
    • Toxicity was markedly elevated in the combination arm, with grade ≥3 adverse events occurring in 85% of patients receiving selinexor plus lenalidomide versus 45% receiving lenalidomide alone (p < 0.001), including higher rates of severe infections (19% vs. 6%, p < 0.01) and gastrointestinal disorders (14% vs. 3%, p < 0.05).
    • The addition of selinexor compromised treatment tolerability and reduced the mean relative dose intensity of lenalidomide from 81% to 68% (p = 0.002), yielding no therapeutic benefit even in patients with high-risk multiple myeloma.
    Read the original sourceBritish Journal of Haematology